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ABSTRACT: A general strategy is introduced for the eﬃcient synthetic access of disulﬁde linked artiﬁcial macrocycles via a Ugi
four-component reaction (U4CR) followed by oxidative cyclization. The double-mercapto input is proposed for use in the Ugi
reaction, thereby yielding all six topologically possible combinations. The protocol is convergent and short and enables the
production of novel disulﬁde peptidomimetics in a highly general fashion.
Cysteine is the prevailing site for covalent post-translationalmodiﬁcation (PTM) in peptides and proteins.1,2 Among
the variety of PTMs, the disulﬁde bond has gained considerable
momentum in biological chemistry as it occurs instantaneously
through oxidative folding in peptides,3 proteins,4 hormones,
enzymes, growth factors, toxins, and immunoglobulins.5
Macrocylization via disulﬁde bond often improves the potency,
rigidity, target selectivity, and stability of proteases and also
stabilizes the secondary structure of peptides.6 Disulﬁdes are
also a common structural motif in therapeutically active
compunds7 and nonribosomal natural products8,9 having
interesting biological activities.10 For example, screening of
disulﬁde-containing macrocyclic libraries has yielded potent
inhibitors of the insulin-like growth factor-1 receptor.11
Unnatural residues such as D-enantiomers of the amino acid,
N-alkylated, α-disubstituted amino acids can be incorporated to
further enhance the biophysical properties of such peptide-
based therapeutics.12 Chemical synthesis is a common
bottleneck approach for producing disulﬁde-rich peptides.
Only a handful of approaches have been developed for a
convenient and straightforward preparation of peptides with
site-speciﬁc disulﬁde connectivity.13 For example, classical
peptide synthesis (solution phase, solid phase, or native
chemical ligation) followed by intramolecular oxidation has
been routinely used to synthesize disulﬁde-containing pep-
tides.14 Importantly, orthogonal protection for Cys has to be
employed, and then the peptides are sequentially transformed
to site-speciﬁc disulﬁdes. Alternative methods are still
demanding for industrial-scale synthesis. In particular, produc-
tion of Cys-rich small peptide sequences in solution or solid
phase can be cumbersome. In order to improve yields and
reduce overall production time, Ugi multicomponent reaction
(U-MCR)15 stands out among all the other methods when it
comes to convergent synthesis of peptides,16 peptidomimet-
ics,17 and macrocycles18 in one or a few simple steps.
Yudin, for example, used protected cysteine peptides as
bifunctional starting material in the Ugi MCR to aﬀord peptide
macrocycle which were subsequently transformed to disulﬁde-
bridged bicyclic peptide macrocycles.19 Surprisingly, however,
the isocyanide derived from enantiopure cysteine and its utility
remains largely unexplored.20 Hence, we herein describe the
synthesis of the chiral cysteine isocyanide and its application in
the Ugi MCR followed by oxidative cyclization to deliver
disulﬁde-bridged cyclic peptidomimetics. Overall, the strategy
relays on the possible variations in the acid, amine and aldehyde
components, having trityl protected thiol as a side chain in
order to obtain disulﬁde-containing cyclic peptidomimetics of
variable ring size (Figure 1).
At the outset of the project, stable enantiopure isocyanide 2
was synthesized. Classical formylation with methyl formate was
employed to synthesize formyl-protected Cys(Trt)-OMe 1
starting from cysteine.21 Nonracemizable dehydrating con-
ditions viz., triphosgene (0.35 equiv) and N-methyl morpholine
(NMM) (2.0 equiv) at −78 °C, were employed to synthesize
isocyanide 2, and its enantiopurity was checked by chiral SFC
[Supporting Information (SI)].22 The quantitative yield of the
isocyanide was obtained as a pale yellow, odor-free solid by
simple recrystallization from diethyl ether (88%). The
isocyanide is bench-stable at room temperature for several
months without any decomposition or racemization.23 The
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isocyanide synthesis was also conducted on a ∼30 g scale
without loss of yield (Scheme 1).
To test the synthetic utility of this novel isocyanide 2, we
carried out a simple Ugi reaction (U-4CR) to prepare peptide-
like adducts. Thus, the commercially available acid component
Fmoc-Cys(Trt)-OH was reacted in the U-4CR, which we
imagined could well be further used for head-to-tail disulﬁde
formation. To probe optimal reaction conditions in a classical
U-4CR, Fmoc-Cys(Trt)-OH, paraformaldehyde, benzylamine,
and isocyanide 2 were reacted in diﬀerent solvents such as
MeOH, triﬂuorethanol (TFE), and hexaﬂuoroisopropanol
(HFIP) under diﬀerent concentrations and temperatures (SI).
Increasing the temperature did not aﬀect the reaction eﬃciency
and yield. Other solvents such as THF, CH2Cl2, and DMF also
decreased the reaction eﬃciency, suggesting that the poor
solubility of the components in either of the solvents may have
compromised the formation of the Ugi product 3a. Thus, we
investigated the use of mixed solvents. Further optimization
resulted in the MeOH/THF/DMF (1:1:0.1, 0.2 M) solvent
mixture which aﬀorded the Ugi product 3a in good 61% yield.
Since our aim was the diverse synthesis of disulﬁde-bridged
peptides via Ugi cyclization (which is called sulfur-switch Ugi
reaction here), any of the components could carry the
protected thiol moiety. Therefore, with functionalized iso-
cyanide 2 in hand, any other mercapto side-chain component
(acid, amine, or aldehyde) should be useful. The scope of the
optimized U-4CR was ﬁrst investigated by changing the amine
and aldehyde components but keeping the acid and isocyanide
constant. Not surprisingly, the used amines and aldehydes
displayed good reactivity in the Ugi reaction (Scheme 2, 3a−i).
For example, the use of methylamine aﬀords N-methylated
peptide adduct 3f in 42% yield upon stirring the reaction
mixture for 30 h at room temperature. Notably, such N-
methylated peptides are diﬃcult to synthesize by classical
peptide synthesis. Tritylamine as ammonia synthon was also
employed to produce N-trityl-protected Ugi adduct 3h, which
further can be deprotected easily.24 A dipeptide acid was also
employed in the Ugi reaction to yield the tetrapeptide adduct 3i
in 52% yield. Moreover 2-(tritylthio)ethan-1-amine was
employed for the ﬁrst time in U-4CR to aﬀord products such
as 3j in 66% yield. This amine is an interesting building block to
generate unprecedented classes of peptidomimetic artiﬁcial
macrocycles through MCR. The trityl-protected mercapto
acetaldehyde was also employed in U-4CR to aﬀord Ugi
adduct 3k in 32% yield, which could serve as promising
synthon for the synthesis of glutathione mimetics through U-
4CR.25
Overall, the U-4CR turned out to be quite general, aﬀording
the Ugi products in moderate to good yield. Simple column
puriﬁcation was employed to isolate the products. When
paraformaldehyde was used, the Ugi product was obtained as a
single diastereomer. Stereochemical retention of the isocyanide
under the reaction conditions was unambiguously shown by
chiral SFC (SI). Other aldehydes aﬀorded the Ugi products as a
mixture of diastereomers.
Having diverse Ugi adducts in hand, we focused on the
peptide cyclization through disulﬁde bond formation. Various
oxidative methods have been previously employed such as air,
DMSO, iodine, thallium salts, mercury salts, and carbon
tetrachloride.26 Recently, NCS was also employed as mild
reagent for peptide disulﬁde cyclization. However, NCS is not
useful when the cysteine is trityl protected.27 Testing diﬀerent
variations, we ﬁnally employed I2 as oxidant for the present
study.28 All of the Ugi products undergo smooth oxidative
cyclization at room temperature (4 h) in a mixture of
dichloromethane and methanol to yield disulﬁde-bridged
Figure 1. Topologically possible Ugi-4CR oxidative disulﬁde backbone
cyclizations resulting in six diﬀerent cyclic scaﬀolds.
Scheme 1. Synthesis of Methyl (R)-2-Isocyano-3-
(tritylthio)propanoate 2
Scheme 2. U-4CR Involving Isocyanide 2 and Disulﬁde
Formationa
aIsolated yields and diastereomeric ratios of Ugi products 3 and
disulﬁdes 4 are provided.
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peptidomimetics in good to excellent yields (Scheme 2, 4a−k).
Interestingly, trityl-protected tertiary amide as well as Boc-
protected amine used are well tolerated under the iodine-
mediated oxidative cyclization, pointing to the possibility of
further orthogonal chemistries.
Since methanol is the common solvent for Ugi and oxidative
cyclization, we also tested the one-pot synthesis of disulﬁde 4a
without isolating the Ugi adduct 3a. However, it resulted in
complex reaction products that resulted in a more diﬃcult
isolation procedure. Therefore, the two-step procedure with
isolation of the intermediate Ugi adduct is advisable.
The obvious advantage of the present method is the reliable
formation of macrocycles through possible variations in the
components. In this context, examples of other cyclizations of
types A, B, and E as shown in Figure 1 were also synthesized in
good yield through our present strategy (Figure 2).29
As an application of our method, we synthesized glutathione
derivative 4p in just two steps (Scheme 3). This tripeptide
glutathione (GSH) is the prevalent nonprotein thiol maintain-
ing the redox status in eukaryotic cells.30,31
Finally, we tested a reaction wherein all four Ugi components
comprise the S(Trt) group to investigate the random formation
of disulﬁde bridges (Scheme 4). One-pot regioselective
formation of two disulﬁde bonds in cysteine-rich peptides has
been reported.32 Several shape isomers such as globular (1−3,
2−4), ribbon (1−4, 2−3), and beads (1−2, 3−4) can be
expected.33 On this basis, a random disulﬁde formation was
carried out under high dilution (Scheme 3). RP-HPLC analysis
of the crude reaction mixture showed three regioisomers
(Figure 3) at distinct peaks at 8.9, 9.6, and 10.7 min, and all the
three regioisomers showed the expected m/z at 634 (M + H)+.
MS/MS fragmentation analysis suggests that the major isomer
formed corresponds to 5a (SI).
In conclusion, we have introduced the concept of “sulfur
switch” in the Ugi reaction, which can lead to a diverse array of
artiﬁcial disulﬁde bridged macrocycles. Ugi reaction followed by
oxidative cyclization (sulfur-switch Ugi reaction) was demon-
strated as an eﬃcient and short synthesis of disulﬁde tethered
peptidic macrocycles. Depending on the choice of the Ugi
components, medium 8-membered macrocycle and larger 16-
membered cycles involving disulﬁde rings can be conveniently
constructed. Examples of all six topologically possible structures
are described. The enantiopure isocyanide derived from L-
cysteine was synthesized for the ﬁrst time as a conﬁgurationally
stable solid and was employed as a bifunctional component in
the Ugi MCR along with the other three components that can
all contain the protected sulfhydryl. The resulting Ugi adducts
were expose to mild oxidative cyclization conditions to deliver
the disulﬁde peptidomimetics. The method described herein is
very versatile and allows synthesis of novel peptidomimetics not
accessible by other methods. The method is operationally
simple, and overall good yields are obtained in just two steps.
Thus, libraries of these compounds will be valuable additions to
screening libraries such as the European Lead Factory.34 Our
work uncovers the interesting opportunities for the eﬃcient
production of novel class of disulﬁde peptides for biophysical
and therapeutic applications. The Ugi products presented
herein oﬀer wide applications for the synthesis peptide
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Figure 2. Representative examples of other topologically possible
disulﬁdes synthesized. Isolated yields and diastereomeric ratios are
given.
Scheme 3. Synthesis of GSH Mimetic 4pa
aIsolated yield is given for major diastereomer isolated from column
chromatography.
Scheme 4. Synthesis of Double Disulﬁde Bridges and
Possible Disulﬁde Isomersa
aConditions: (1) (a) TFE/THF (1:0.5, 0.2 M), rt, 24 h, (b) single
diastereomeric Ugi product 3q was isolated and used for cyclization;
(2) I2, CH2Cl2/MeOH (10:1), rt, 4 h.
Figure 3. RP-HPLC analysis of the regiosimers from the crude
reaction mixture after random cyclization with I2.
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